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Abstract 14 
One of the leading causes of the hand, foot and mouth disease (HFMD) is Enterovirus 71 15 
(EV-A71), displaying symptoms such as fever and ulcers in children but some strains can 16 
produce cardiopulmonary oedema which leads to death. There is no FDA-approved 17 
vaccine for prevention of severe HFMD. The molecular determinants of virulence for EV-18 
A71 are unclear. It could be a single or a combination of amino acids that determines 19 
virulence in different EV-A71 genotype/sub-genotypes. Several EV-A71 strains bearing 20 
single nucleotide (nt) mutations were constructed and the contribution of each mutation to 21 
virulence was evaluated. The nt(s) that contributed to significant reduction in virulence in 22 
vitro were selected and each mutation was introduced separately into the genome to 23 
construct the multiply mutated EV-A71 strain (MMS) which carried six substitutions of 24 
nt(s) at the 5’-NTR (U700C), VP1-145 (E to G), VP1-98E, VP1-244K and G64R in the 25 
vaccine seed strain that had a partial deletion within the 5’-NTR region (nt. 475-485) of 26 
∆11bp. In comparison to the wild type strain, the MMS showed low virulence as it 27 
produced very low RNA copy number, plaque count, VP1 and had 105-fold higher 28 
TCID50, indicative of a promising LAV candidate that should be further evaluated in vivo. 29 
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Abbreviations 32 
EV-A71: Enterovirus 71; PV: Poliovirus; 5’-NTR: 5’- non translated region; aa: amino 33 
acid; nt: nucleotide; CPE: cytopathic effects; MOI: multiplicity of infection; RD: 34 
Rhabdomyosarcoma; PFU: plaque forming units; TCID50: 50% tissue culture infectious 35 
dose; VP1: Viral protein; LAV: live attenuated vaccine; MMS: multiply mutated strain. 36 
1. Introduction 37 
In 2016, there were approximately 2.14 million reported cases of Hand, Foot and 38 
Mouth Disease (HFMD), including 204 deaths in China (WHO Western Pacific Region 39 
Surveillance Summary 2016). Vaccines against the Hand, Foot and Mouth Disease 40 
(HFMD) are highly desirable as HFMD has evolved to become a severe global and life 41 
threatening disease, ravaging lives of young children in cyclical epidemics in the Asia 42 
Pacific. With rising concern about the virulence of EV-A71, there is an urgent need for a 43 
vaccine against EV-A71 to be produced that is endorsed by the United States Food and 44 
Drug Administration (FDA). Up to date, several biopharmaceutical companies in China 45 
have ended their Phase III Clinical Trials, producing the inactivated vaccine (IV) 46 
adjuvanted with alum, against the sub-genotype C4a. Although the efficacy of their IVs 47 
was more than 90% against mild HFMD, it only conferred 80% protection against severe 48 
HFMD (Chong et al., 2015). The IV induces good humoral immunity but is deficient in the 49 
cellular arm of immunity, which is needed for long-term protection. Therefore, there is a 50 
need to develop other types of vaccines. The development of live attenuated vaccines 51 
(LAVs) is desirable as it is known to induce excellent immunogenicity, can elicit both 52 
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humoral and cellular immunity and able to confer live-long immunity. A LAV from the 53 
BrCr strain (S1-3’) prototype strain carrying mutations in the 3’-NTR, 3Dpol and 5’-NTR 54 
was constructed by Arita et al. (2007). Although there was reduced virulence, mild 55 
neurological symptoms were still observed in the 3 cynomolgus monkeys immunized with 56 
the EV-A71 (S1-3’) strain. Hence, the plan to use this strain as a LAV was discontinued 57 
(Arita et al., 2007). 58 
Before an effective LAV can be developed, there is a need to identify the genetic 59 
determinants of virulence. Once the specific determinants of virulence in EV-A71 have 60 
been identified, rational design of the LAV can be carried out by site directed mutagenesis 61 
(SDM) to target the specific amino acids that are associated with virulence. Classification 62 
of genetic determinants of virulence in EV-A71 by analyzing differences in the genome has 63 
been published. Sequence comparison between virulent and non-virulent strains showed 64 
that 4 amino acids (aa) in VP1 (GlyP710/GlnP710/ArgP710/GluP729), 1 aa. in the 2A protein 65 
(LysP930) and 4 nucleotides (nt) in the 5’-NTR (GP272, UP488 and AP700/UP700) could be 66 
genetic determinants for virulent EV-A71 sub-genotype C4 strains (Li et al., 2011). In 67 
addition, it was postulated that the EV-A71 mutant displaying high-fidelity (sub-genotype 68 
B4) with a single aa. change, (G64R) in its RNA-dependent RNA polymerase (RdRP) 69 
enzyme greatly reduced viral pathogenicity in vivo (Meng and Kwang, 2014). Kataoka et 70 
al. (2015) found that if the aa. glutamic acid was present at position 145 of VP1 (VP1-71 
145E) in EV-A71 (sub-genotype C1), the virus induced neuro-pathogenesis and viremia 72 
more efficiently in cynomolgus monkeys than if glycine (G) was found at residue 145 73 
(VP1-145G) (Kataoka et al., 2015).  74 
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The analysis of significant molecular determinants of virulence that were responsible 75 
for the attenuated phenotypes of the Sabin Oral Polio Vaccine (OPV) strains was due to the 76 
complete sequences of 3 poliovirus (PV) genomes and the development of infectious PV 77 
cDNA clones. For example, the Sabin 1 strain differed from its wild type strain with 57 nt. 78 
substitutions (Nomoto et al., 1982). It was found that the A480G in the IRES region is the 79 
most vital determinant of virulence that contributed to the attenuation in the Sabin 1 strain. 80 
It could be possible that nt. 480 affects the formation of a structure in the 5’-NTR 81 
responsible for neuro-virulence (Kawamura et al., 1989). For the Sabin 2 strain there were 82 
only 2 nt. substitutions (nt. 481 in IRES and nt. 2909 in VP1), whereas a total of 10 nt. 83 
substitutions were discovered for the Sabin 3 strain. Amongst the 10, there were 3 84 
significant molecular determinants of virulence (C274U in IRES, C2034U in VP3, and 85 
U2493C in VP1 (Chia et al., 2014; Huang et al., 2013; Westrop et al., 1989). Virulent 86 
strains of EV-A71 are referred to as the new polio as it is neurotropic. Both the 87 
enteroviruses share very high sequence homology, particularly in the 5’-NTR. EV-A71 88 
contains a similar nt. G481 that is a significant molecular determinant of neuro-virulence in 89 
the PV wild type. Hence, studies on PV in earlier research could be good references to 90 
design attenuated EV-A71 viruses. 91 
With advances in molecular biology, novel approaches to viral attenuation can be 92 
further studied such as altered replication fidelity and codon de-optimization. As high 93 
mutation rates often hinder the effectiveness of a LAV, increasing the replication fidelity 94 
can potentially attenuate whole virus population, culminating to a population collapse with 95 
the absence of mutating vital immunogenic epitopes. For all species, codon pair usage is 96 
biased and some codon pairs are utilized more often than others (Gutman and Hatfield, 97 
1989). A big part of the genetic code is redundant as contiguous pairs of aa. can be coded 98 
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for by 36 alternate pairs of synonymous codons (Buchan et al., 2006; Sharp et al., 1986). 99 
Through the substitution of alternate but synonymous codons within the genome sequence, 100 
this would produce different codon pairs but expressing a similar sequence of amino acids. 101 
The proteins expressed from these viruses would elicit the same immune response as the 102 
wild type viruses. Burns et al. (2006) replaced half of the total codons in the Sabin type 2 103 
OPV strain (within capsid region) with less frequently utilized synonymous codons. They 104 
discovered that processing and manufacturing of viral proteins were unaffected but viral 105 
fitness was reduced (Burns et al., 2006). Subsequently, they replaced natural capsid region 106 
codons with synonymous codons that had an abundance of CpG and UpA dinucleotides. 107 
Codon-deoptimized PVs were produced and these viruses had significantly lower overall 108 
fitness as indicated by lower viral plaque number and virus yields (Burns et al., 2009).  109 
Mueller et al. (2006) introduced the biggest number of less frequently utilized 110 
synonymous codons in the capsid region of PV type 1 Mahoney. They found a significant 111 
decrease in replicative fitness and number of infectious viral progeny. As compared to the 112 
wild type, there was also reduction in the viral infectivity up to approximately 1,000-fold 113 
and decrease in genome translation (Mueller et al., 2006). The codon deoptimized viruses 114 
remained attenuated after repeated cell passages and were genetically stable with minimal 115 
risk of reversion (Burns et al., 2006; Mueller et al., 2006). As these viruses have sequences 116 
that are fairly divergent from circulating wild type viruses, probabilities for further 117 
recombination and production of vaccine-derived variants will be reduced. In addition, the 118 
codon deoptimized attenuated viruses were genetically stable and showed low risk of 119 
reversion. 120 
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Previously, we had mutated the EV-A71 virus (sub-genotype B4 virus; 121 
5865/Sin/000009) by substitutions at positions 475, 486, and 487 as these 3 nucleotides 122 
corresponded to the significant molecular determinants of neuro-virulence in PV Sabin 123 
strains 1, 2 and 3. In EV-A71, we have introduced a partial deletion (PD) (deletion from nt. 124 
475-485 in the 5’-NTR) as it is considered to be genetically more stable than single site 125 
mutations. Compared to mutants with specific nt replacements at 475, 486 and 487, the EV-126 
A71 PD mutant carrying the 11 base pair deletion demonstrated the lowest viral RNA copy 127 
number, plaque count and VP1 capsid protein. The PD mutant demonstrated low virulence 128 
and therefore, could possibly be a good potential seed strain for designing a LAV candidate 129 
(Yee et al., 2016).  130 
In this study, we constructed several codon deoptimized EV-A71 viruses by 131 
substituting single synonymous codon at positions VP1 (98E), VP1 (242K), VP1 (244K), 132 
VP2 (149K) and 2A (930K) to assess the outcome of each codon deoptimization on 133 
replication fitness in Rhabdomyosarcoma (RD) cells. If the LAV has single site mutations, 134 
there is a strong possibility for reversion to occur. However, if it bears a short deletion and 135 
further mutations added to the genome, there is a possibility to reduce reversion and 136 
increase the stability of LAVs. In addition, a better attenuated mutant was constructed by 137 
introducing multiple mutations into the EV-A71 mutant PD. Hence, we also constructed a 138 
multiply mutated EV-A71 strain (MMS) by substituting 6 nucleotides at the 5’-NTR 139 
(U700C), VP1-145 (E to G), VP1 (98E), VP1 (242K), VP1 (244K), G64R in the mutant PD 140 
(∆11bp in 5’-NTR). We evaluated the attenuation of virulence of the MMS in RD cells 141 
such as cytopathic effects, viral infectivity by tissue culture infectious dose (TCID50), 142 
plaque counts, production of VP1 and RNA copy number.  143 
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2. Materials and Methods  144 
2.1 Tissue culture of RD cell line 145 
Human Rhabdomyosarcoma cells (RD, ATCC # CCL-136) were propagated in Dulbecco's 146 
modified Eagle's Minimal Medium/F-12 (DMEM/F-12, Invitrogen, USA), that was 147 
supplemented with 1.5% NaHCO3, 10% fetal bovine serum (FBS) (Gibco, USA), 1% non-148 
essential amino acids and 1% penicillin/streptomycin antibiotics. The cells were grown at 149 
37°C in 5% CO2 until they reached confluence. 150 
2.2 Virus propagation and storage  151 
A 75cm2 tissue culture flask with 100% confluent Rhabdomyosarcoma (RD) cells was 152 
infected with 100 μl of virus supernatant. The flask was incubated for 1 h at 37°C and 153 
replaced with fresh DMEM supplemented with 2% FBS. The flask was incubated at 37°C 154 
for 24 - 48h and observed for cytopathic effects (CPE). The culture supernatants were 155 
harvested and freeze-thawed 3 times. The supernatants were then centrifuged at 10,000 x g 156 
for 20 minutes at 4°C to remove cell debris. The harvested supernatants were then stored at 157 
-80°C until further use. 158 
2.3 Viral RNA Extraction  159 
This process was performed using QIAamp® Viral RNA Mini Kit (Qiagen, Calif., USA). 160 
The principle was based on the selective binding properties of a silica-gel based membrane 161 
together with micro spin technology to extract viral RNA. The samples were lysed with a 162 
buffer which aids in denaturing RNases. The RNA was attached to the membrane which 163 
was then washed two times with buffers. The RNA was eluted with DEPC-treated water. 164 
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An aliquot of 140 μl taken from the samples were processed and the viral RNA was eluted 165 
in 50 μl of elution buffer (Qiagen, Calif., USA).  166 
2. 4 Reverse transcription of EV-A71 RNA 167 
The purified EV-A71 genomic RNA was converted into cDNA with the SuperScript® IV 168 
First Strand Synthesis System (ThermoFisher Scientific, Calif., USA). Each mixture 169 
contained 50 mM Tris-HCl (pH 8.3), 4 mM MgCl2, 10 mM DTT, 50 mM KCl, 0.5 mM 170 
dTTP, 0.4 MBq/mL [3H]-dTTP, 0.4 mM poly(A) oligo (dT)12-18 and SuperScript® IV RT 171 
enzyme in 20 μL for 10 min at 37°C. 172 
2.5 Cloning of EV-A71 cDNA into the pCR-XL-TOPO vector 173 
The pCR-XL-TOPO vector was supplied with 3’ thymidine (T) overhangs. The PCR 174 
products carrying 3’ deoxyadenosine (A) overhangs were cloned in the pCR-XL-TOPO 175 
vector (Invitrogen, Calif., USA) based on the manual from the manufacturer. About 100 176 
ng/μl of the cDNA template was prepared. An aliquot of 4 μl of the cDNA template in TE 177 
buffer was mixed with 1 μl (10 ng/μl) of plasmid DNA and incubated at room temperature 178 
for 30 min. Thereafter, 1 μl 6X TOPO stop solution was added to prevent the reaction from 179 
proceeding further. The recombinant pCR-XL-TOPO_EV71 plasmid was then transformed 180 
into E. coli XL10-Gold® Ultra competent Cells (Invitrogen, Calif., USA). 181 
2.6 Site-directed mutagenesis 182 
Mutations were introduced by using the QuickChange Lightning Site-Directed Mutagenesis 183 
Kit (Agilent Technologies, Calif., USA). A pair of primers consisting the desired mutation 184 
was designed for the recombinant pCR-XL-TOPO_EV71 vector. The cycling parameters 185 
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for the QuikChange Lightning Site-Directed Mutagenesis Method were: 95°C for 2 min for 186 
initial denaturation, followed by 18 cycles of 95°C for 20 secs, 60°C for 10 secs, 68°C for 5 187 
min 30 sec and 68°C for 5 min for final elongation. Approximately 2 µl of DpnI enzyme 188 
was added to each amplification reaction to digest the non-mutated supercoiled dsDNA. 189 
The enzyme mix was transformed into XL10-Gold ultracompetent E. coli cells. Colonies 190 
were selected on LB + Kanamycin plate before 3 purified colonies were screened by 191 
sequencing. 192 
2.7 Construction of a partial-deletion in the 5’-NTR of EV-A71  193 
A partial deletion (PD) (deletion from nt. 475-485 in the 5’-NTR) was constructed in the 194 
EV-A71 genome with a pair of 24-mer forward and 24-mer reverse primers. The mutation 195 
was introduced using the Q5® Site-Directed Mutagenesis Kit (New England Biolabs, USA) 196 
[(Chua et al., 2008)]. The presence of the deletion was confirmed using the nucleotide 197 
Basic Local Alignment Software (BLAST by NCIB).  198 
2.8 Restriction digestion of plasmid DNA  199 
Digestion of pCR-XL-TOPO_EV71 plasmid was carried out with restriction enzyme EagI 200 
(New England BioLabs, Massachusetts, USA). Briefly, this was carried out in an 201 
Eppendorf tube containing 15 μg of plasmid DNA, EagI in the corresponding 1X digestion 202 
buffer. All reactions were incubated for at least 2 hours at 37oC specified by the 203 
manufacturer. 204 
2.9 Phenol-chloroform DNA purification  205 
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The linearized DNA was added with an equal volume of phenol/chloroform/isoamyl 206 
alcohol (Invitrogen, Calif., USA) and subsequently, vortexed for 1 minute. Solvent and 207 
aqueous phases were visible after centrifugation at 15, 000 x g for 10 minutes. The aqueous 208 
phase was aspirated and added with an equal volume of chloroform/isoamyl alcohol 209 
(Invitrogen, Calif., USA). This step was necessary to remove the remaining phenol. After 210 
10 minutes of centrifugation at 15,000 x g, the aqueous phase was aspirated and 1/10 211 
volume of 3 M sodium acetate (pH 5.2) was added and vortexted. An aliquot of 1 volume 212 
of isopropyl alcohol was added and kept at -20°C for 2 h. The precipitated DNA was 213 
centrifuged at 15,000 x g for 30 minutes at 4°C and the DNA pellet was rinsed with 70% 214 
ethanol. After air-drying, the pellet was dissolved with TE buffer and DNA concentration 215 
determined. 216 
2.10 In vitro transcription of SP6 promoter 217 
RNA transcription was performed utilizing the RiboMAX™ Large Scale RNA Production 218 
System-SP6 (Promega, Calif., USA). The reaction mixture was prepared in a 100 µl 219 
reaction volume according to the manufacturer’s instructions. The reaction mixture was 220 
incubated at 37°C for 2 h, followed by addition of DNase for 30 minutes to remove parental 221 
DNA. The transcribed RNA was purified with the Illustra Microspin G-50 column (GE 222 
Healthcare Life Sciences, Chicago, USA) before transfection in RD cells (Han et al., 2010).  223 
2.11 Transfection of infectious RNA 224 
Overnight grown RD cells (1.5 x 105 cells/well in a 24-well plate) were prepared and used 225 
for transfection. Approximately 1μg of RNA was transfected into a well within the 24-well 226 
plate. Prior to transfection, the growth medium was removed and replaced with Opti-MEM 227 
P a g e  | 11 
 
11 
 
(Invitrogen, Calif., USA). Transfection mix was prepared with a ratio of 2 μl of 228 
Lipofectamine 2000 reagent to 1 μg of RNA. The RNA-containing Opti-MEM was mixed 229 
with the Lipofectamine 2000 reagent containing Opti-MEM and incubated for 20 min at 230 
room temperature. Thereafter, the RNA-lipofectamine mixture was added to the RD cells 231 
drop-by-drop. Four hours after transfection, the transfection medium was removed and 232 
substituted with 500 μL 10% FBS DMEM without Penicillin/Streptomycin. 233 
2.12 Quantitation of viral infectivity by tissue culture infectious dose (TCID50) assay 234 
RD cells (3.0 x 104 cells/well in a 96-well plate) were prepared a day before. Using DMEM 235 
serum-free media as a diluent, 10-fold serial dilutions of the harvested virus supernatant 236 
were carried out in quadruplicates in a 96-well plate. The negative control wells contained 237 
infected RD cells (without any virus supernatant). The plate was incubated at 37oC and 238 
observed daily for CPE for up to 48h. 239 
2.13 Viral RNA copy determination by real-time RT-PCR 240 
With the RNeasy extraction kit (Qiagen, Calif, USA), viral RNA was extracted from the 241 
virus suspension of transfected RD cells. Real-time PCR was carried out utilising the 242 
TouchTM Real-Time PCR Detection System (Bio-Rad, CFX96) and the SensiFAST™ 243 
Probe No-ROX One-Step Kit (BioLine, California, USA). The 20 μl reaction mixture 244 
contained 4 μl of RNA template, 10 μl of 2x SensiFAST Probe No-ROX One Step Mix, 0.8 245 
μL forward and reverse primers (10 uM), 0.2 μL probe (10 uM), 0.2 μl reverse transcriptase 246 
enzyme, and 0.4 μL RiboSafe RNase inhibitor. The reaction was performed for one cycle at 247 
48oC for 10 min, 95°C for 2 min, followed by 40 cycles at 95°C for 5s and 60°C for 20s 248 
using 0.2 mL PCR tubes and caps (Bio-Rad, Calif, USA).  249 
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2.14 VPl determination by western blot 250 
Cellular proteins were extracted from harvested viral suspension of infected cells using 251 
RIPA lysis buffer (1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 252 
sulfate, 50 mM Tris, pH 8.0, and protease inhibitor mixture). The protein samples were 253 
mixed with an equal volume of 4X SDS protein sample buffer (240 mM Tris-HCl, pH 6.8, 254 
8% SDS, 5% β-mercaptoethanol, 40% glycerol and 0.04% bromophenol blue). The protein 255 
lysates were run on SDS-PAGE and transferred to nitrocellulose membrane (Millipore, 256 
Calif., USA). Thereafter, the membrane was blocked with 5% skim milk powder (Sigma-257 
Aldrich, St Louis, USA) in Tris-Buffered Saline and Tween 20 (TBST) buffer for 1 h on an 258 
orbital shaker at room temperature. The membrane was then added with anti-enterovirus 259 
VP1 mouse monoclonal primary antibody (Merck, Calif., USA) diluted in 2.5% TBST 260 
overnight at 4°C. The next day the nitrocellulose membrane was washed three times with 261 
TBST, for 10 min each wash, prior to incubation with anti-mouse HRP secondary antibody 262 
(Sigma Aldrich, St Louis, USA) diluted in 2.5% TBST. After hybridization, the membranes 263 
were washed three times with TBST, for 10 min each wash, and then detected by chemi-264 
luminescence using ImageQuant (GE Healthcare Life Sciences, Calif., USA). 265 
2.15 Quantitation of viral titer by plaque assay 266 
A 6-well plate with 6 X 105 RD cells/well was seeded before viral infection the subsequent 267 
day. Serial 10-fold dilutions of viral suspension were prepared and 1 mL of each dilution 268 
was added to the cells for 1 h at 37oC. After viral attachment to the cells, the dilutions were 269 
aspirated and substituted with 2 mL of 0.9% w/v high viscosity carboxymethylcellulose 270 
(CMC) (Sigma Aldrich, St Louis, USA). After 48 h incubation, the CMC was removed and 271 
the cells were fixed with 10% formalin for 10 min. After fixation, the formalin was 272 
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removed and replaced with 0.5% crystal violet solution for 20 min incubation. The plaques 273 
were visible against a white background and the plaque forming units (PFU) were 274 
calculated for each EV-A71 mutant. 275 
2.16 Bioinformatics Analysis 276 
The protein sequence of EV-A71 viral proteins was analyzed and the amino acid sequences 277 
were aligned with the Clustal method of DNASTAR MegAlign. Predictions of 5’NTR 278 
secondary structures of probable base pairs predictions, which might include pseudoknots 279 
was conducted by using databases such as RNA Structure at Rochester University: 280 
http://rna.urmc.rochester.edu/RNAstructureWeb/index.html and the mfold Web Server at 281 
http://molbiol-tools.ca/RNA_analysis.htm. 282 
2.17 Statistical Analysis 283 
Based on the data of at least three independent biological replicates, the mean ± standard 284 
deviation was calculated. Statistical significance was determined with the Mann-Whitney 285 
test, whereby a p value of < 0.05 was considered as statistically significant. 286 
3. Results 287 
3.1.1 Cytopathic effects (CPE) caused by EV-A71 mutants 288 
The EV-A71 sub-genotype B4 virus (5865/Sin/000009) was genetically engineered to 289 
produce several codon deoptimised EV-A71 viruses by substituting single synonymous 290 
codon at positions VP1-98E, VP1-242K, VP1-244K, VP2-149K and 2A-930K. We also 291 
substituted several nucleotides (nt) at three positions within the 5’-NTR (C272U, U488C, 292 
U700C), VP1-E145G and the 3Dpol region (G64R). The effects of these changes were 293 
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assessed by the inhibition of CPE in RD cells (Table 1). Upon transfection into RD cells 294 
with a multiplicity of infection (MOI) of 0.1, mutant C475U still caused the lowest CPE 295 
(Figure 1m) when compared to the wild type EV-A71 (Figure 1q). CPE was observed as 296 
round cells that lifted off the surface and there was abundant CPE observed with the EV-297 
A71 wild type strain 41 (Figure 1q).  298 
Mutant EV-A71 PD caused much lower CPE (Figure 1e) when compared to mutants 299 
C272U (Figure 1i) and 2A-930K (Figure 1h). Out of all the mutants, VP2-149K displayed 300 
abundant CPE (Figure 1g) as observed from the shrunken and rounding up of many RD 301 
cells. Mutants VP1-242K (Figure 1b), U488C (Figure 1j) and A486G (Figure 1n) 302 
demonstrated an intermediate amount of CPE after RD cell transfection. Based on the 303 
morphology shown in Figure 1c, 1f and 1o, infection of RD cells by mutants VP1-244K, 304 
VP1-E145G and G487A showed minimal CPE as cells had the healthy spindle-like shape 305 
of multiplying RD cells when compared to EV-A71 wild type sub-genotype B4  (Figure 306 
1q). There were not many dead cells floating and showed similar morphogy as the negative 307 
control (uninfected RD cells) (Figure 1p). 308 
A multiply mutated EV-A71 strain (MMS) was constructed by substituting six 309 
nucleotides at the 5’-NTR (U700C), VP1-145 (E to G), VP1 (242K), VP1 (98E), VP1 310 
(244K), G64R in the strain that consisted of a partial deletion in the 5’-NTR (∆11bp). The 311 
MMS showed an absence of CPE (Figure 1l), displaying similar morphology as the 312 
negative control (Figure 1p). Lower CPE was observed in the MMS in comparison to the 313 
codon deoptimised mutant VP1-98E (Figure 1a) and G64R (3Dpol) (Figure 1d). The 314 
morphology displayed by these EV-A71 mutants showed vast disparity from the abundant 315 
CPE observed for the postive control (wild type strain 41) (Figure 1q).  316 
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3.1.2. Quantitation of viral infectivity by tissue culture infectious dose (TCID50) assay 317 
The tissue culture infectious dose (TCID50) is a measurement of the amount of virus 318 
that elicits cytopathic effect in 50% of the transfected cell cultures. The MMS demonstrated 319 
the highest TCID50 of 3.16 X 10
8 in comparison to the wild type EV-A71 strain (2.13 X 320 
103) (Figure 2). This indicates that the MMS would need a significantly higher amount of 321 
virus (105-fold more) to elicit a cytopathic effect in 50% of the of the transfected cultures. 322 
EV-A71 mutants VP1-E145G and VP1-244K also had 105-fold increased TCID50 value 323 
(3.16 X 108) in comparison to the positive control, indicative that the mutants showed a 324 
reduction in infectivity. EV-A71 mutants with SDM at VP1-242K (7.02 X 105) and G487A 325 
(7.50 X 105) demonstrated greater than 102-fold rise in TCID50 value in comparison to the 326 
positive control (EV-A71 wild type). EV-A71 mutant VP1-98E (1.16 X 106) and PD 327 
displayed 103-fold increases in TCID50 value in comparison to the wild type (2.13 X 10
3). 328 
An examination of the TCID50 values implicates that mutants carrying single mutations in 329 
the VP1, for example, E145G and 244K as well as the MMS required the highest quantity 330 
of viruses to elicit cytopathic effect in 50% of the transfected cell cultures. The results 331 
indicated a high degree of attenuation in the two SDM mutants and the MMS carrying 332 
multiple mutations in its genome (Figure 2).  333 
3.1.3 Viral RNA copy determination by real-time RT-PCR 334 
  Assays such as the viral RNA copy number quantitation and TCID50 of various 335 
mutant strains will allow a better quantitative comparison of the growth aspects of the 336 
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different mutant strains. The viral RNA copy number of the EV-A71 mutant strains was 337 
assessed after transfection into RD cells. The positive control (wild type strain 41) 338 
produced the highest amount of viral RNA copy number (5.8 X 104). Significantly lower 339 
RNA copy numbers were detected for mutants C475U (1.02 X 102) and PD (1.05 X 102) 340 
(Figure 3). When the mutant strains were examined in RD cells, a few new mutations seem 341 
to decrease viral replication. It was demonstrated that mutant VP1-244K gave a yield of 2.9 342 
X 102 RNA copy number which was 100-times lesser than the positive control viral RNA 343 
copy number (5.8 X 104). It appeared that mutant VP2-149K yielded the greatest amount of 344 
viral RNA copy number of 2.9 X 104 in comparison to the positive control (wild type strain 345 
41). As the RNA copy number is still approximately half to that of the wild type strain, this 346 
shows that there remains some degree of attenuation.  347 
In addition, the mutant VP1-E145G displayed significant decreases in viral RNA copy 348 
number (4.5 X 102) (Figure 3). The MMS yielded markedly low viral RNA copy number of 349 
1.3 X 102 and substantially deceased the viral RNA copy number to almost 102-fold less in 350 
comparison to the positive control (5.8 X 104). A reduction of RNA copy number was also 351 
expressed by mutants VP1-98E and G64R (3Dpol) at 7.8 X 102 and 1.4 X 103, respectively.  352 
3.1.4 VP1 determination by western blot 353 
Western blotting with monoclonal antibodies targeted at the VP1 capsid protein of 354 
EV-A71 could enable the detection of the viral capsid protein and be an indirect indicator 355 
of the ability of the various mutant strains to produce viable viral particles. Cellular protein 356 
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lysate was harvested from the supernatants of infected RD cells and sodium dodecyl sulfate 357 
polyacrylamide gel electrophoresis (SDS-PAGE) was performed to separate the EV-A71 358 
proteins based on molecular weight (MW). A singular band was revealed at a MW of 37 359 
kDa which corresponds to the VP1 monomer (Figure 4). 360 
Based on the Western blot analysis, cellular proteins from RD cells transfected with 361 
the positive control (wild type EV-A71) (Figure 4, Lane 16) showed the greatest VP1 362 
protein amount (36 kDa). There was hardly any VP1 observed for mutant C475U (Figure 4, 363 
Lane 8), mutant G487A (Figure 4, Lane 5) and mutant PD (Figure 4, Lane 13). The results 364 
were consistent with the cytopathic effect, TCID50 infectivity and viral RNA copy number. 365 
There seems to be a few nt. in the EV-A71 viral genome that are attenuating the virus as the 366 
quantity of VP1 for some of the mutant strains were significantly lesser than the positive 367 
control (Figure 4, Lane 16). The mutant MMS (Figure 4, Lane 6), mutant VP1-244K 368 
(Figure 4, Lane 10) and mutant VP1-E145G (Figure 4, Lane 3) showed much lesser VP1 369 
quantity in comparison to the positive control (wild type strain 41) (Figure 4, Lane 16). 370 
Although each mutant had caused significant reduction of virulence in terms of VP1, viral 371 
RNA copy number, and TCID50 values, the introduction of all the mutations together in a 372 
single genome will enable increased genetic stability. 373 
3.1.5 Quantitation of viral titre by plaque assay 374 
Plaque numbers produced by the different EV-A71 mutants were assessed in RD 375 
cells by plaque assays. Our objective is to evaluate the ability of the various mutants to 376 
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form plaques. RD cells infected with the positive control (wild type EV-A71 strain 41) 377 
gave the largest plaque number (8.0 x 108 PFU/mL). The smallest plaque numbers were 378 
produced by the MMS (1.2 x 104 PFU/mL) and mutant C475U (7.0 x 104 PFU/mL) (Figure 379 
5).  380 
Based on Figure 6, there are a few nt. in EV-71 viral genome that appear to attenuate the 381 
virus. The EV-A71 mutant VP1-E145G gave a yield of 3.5 x 105 PFU/ml and the mutant 382 
VP1-244K produced a decrease in number of plaques (2.5 x 105 PFU/ml) in comparison to 383 
the EV-A71 wild type (5865/Sin/000009), although the plaque counts were higher than the 384 
mutant PD (1.0 x105 PFU/mL). The mutant VP1-98E also showed reduced plaque number 385 
(7.5x105 PFU/mL). As there was reduction in viral growth, this was indicative that the 386 
plaque forming capability has been decreased markedly for several mutant strains. This 387 
signifies that there would be weaker viremia due to a reduction in viral copy number as 388 
viral load induces pathogenicity. 389 
4. Discussion 390 
In our previous investigation, we genetically engineered the EV-A71 sub-genotype B4 391 
(5865/Sin/000009) through site directed mutagenesis via the substitution of nt. at positions 392 
475, 486, and 487 as these nts. were the molecular determinants of neurovirulence in PV 393 
Sabin strains 1, 2 and 3. We also introduced a partial deletant (PD) in the 5’-NTR region 394 
(deletion from nt. 475-485 in the 5’-NTR) as it may be genetically more stable than single 395 
site mutations. The study concluded that the EV-A71 partial deletant (PD) and mutant 475 396 
demonstrated the lowest RNA copy number, plaques and VP1 protein followed by EV-A71 397 
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mutants 487, 5262, 158 and 486 in the order listed. This shows that the mutant PD could 398 
serve as a potential vaccine seed strain to carry beneficial mutations that will further 399 
attenuate or stabilize it to become a good LAV candidate (Yee et al., 2016).  400 
In addition, better attenuated mutants could be constructed by introducing multiple 401 
mutations into the attenuated EV-A71 mutant PD. With advances in molecular biology, 402 
novel approaches to viral attenuation can be further studied such as altered replication 403 
fidelity and codon deoptimization. As for the latter approach, synonymous codons can be 404 
substituted all over a viral genome, hence preventing a decrease in immunogenicity and 405 
minimal possibility of reversion to wild type virulence. Studies on codon bias on viral 406 
multiplication and pathogenicity of poliovirus (PV) have been reported (Burns et al., 2009; 407 
Mueller et al., 2006). Interestingly, many studies have discovered that the deoptimized 408 
viruses remained attenuated after repeated passages and hence, were genetically stable with 409 
minimal risk of reversion. As both PV and EV-A71 share very high percentage of sequence 410 
homology hence, the codon deoptimization research on PV published in recent work could 411 
be referred to in the production of highly attenuated EV-A71 viruses. Therefore, we 412 
constructed several codon deoptimized EV-A71 viruses by substituting synonymous codon 413 
at positions VP1 (98E), VP1 (244K), VP1 (244K), VP2 (149K) and 2A (930K) to evaluate 414 
the effect of each codon deoptimization on replication fitness in Rhabdomyosarcoma (RD) 415 
cells. 416 
Thus far, there is no quantification of the effects of different amino acids in the viral 417 
genome on virulence except for studies of comparison of nt. and amino acid sequences 418 
between virulent and non-virulent strains. In addition, most of the studies using 419 
comparative analysis between the strains were of sub-genotype C4. For example, 4 aa. 420 
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differences in the VP1 region (GlyP710/GlnP710/ArP710/GluP729), LysP930 in 2A region and 4 421 
nts. in the 5’-NTR region (AP700/UP700, GP272, UP488) were found after aligning the VP1 422 
sequences between fatal and mild EV-A71 strains (sub-genotype C4) (Li et al., 2011). 423 
These aa. demonstrate that there were several genetic determinants for virulent EV-A71 424 
strains and these aa. could possibly be responsible in changing mild strains into fatal ones. 425 
This is to be expected as the 5’-NTR was responsible for cap-independent translation of 426 
viral proteins. As such, research reported in the study by Li et al. (2011) served as a 427 
reference to assess quantitatively the degree of attenuation of EV-A71 mutants constructed 428 
in this study to carry mutations C272U, U488C and U700C in the viral genome.  429 
The importance of a C104U nt. substitution in the 5’NTR region (between the 430 
cloverleaf and stem-loop II region) of CV-A16 was first demonstrated by Li et al. (2016). 431 
This mutation could significantly lower RNA replication and inhibit translational activity in 432 
vitro and also in the neonatal ICR mice. They identified that the nt. C104U could possibly 433 
be a molecular determinant of virulence for the lethal CV-A16 strain. The mutation affected 434 
the binding of the heterogeneous nuclear ribonucleoprotein K (hnRNP K) and A1 (hnRNP 435 
A1) with the 5’NTR, hence reducing translational rates. This was discovered by aligning 436 
with nt. sequences in the 5’NTR of the prototype G10, the non-lethal SHZH05 strains and 437 
the lethal Changchun024 strain. Thereby, the authors constructed infectious mutants of CV-438 
A16 with different nt. substitutions in the 5’-NTR (Li et al., 2016). Similar to the finding 439 
that the 5’-NTR region is also carrying the specific genetic determinants for virulent EV-440 
A71 sub-genotype C4 strains, this study reporting specific nt. changes in the 5’-NTR of 441 
CV-A16 with subsequent reductions in viral replication lends credence that the 5’-NTR 442 
region is a virulence-associated site.  443 
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In addition, Caine et al. (2016) discovered that a single mutation in VP1-244 (K244E) 444 
was crucial for mouse-adapted EV-A71 (mEV-A71) virulence and expanded tissue tropism 445 
in adult interferon-deficient AG129 mice. They also found a new VP1 mutation (H37R) 446 
that was important for K244E recovery in primate cell culture (Vero cells). The authors 447 
postulated that the H37R/K244E interaction is pertinent for replication in primate cells but 448 
the K244E mutant could replicate alone in a murine model (Caine et al., 2016). Three 449 
positions were demonstrated to be conserved among neurovirulent strains but were 450 
different from sub-genotype C4a strains carrying mild HFMD (ValP1148/IleP1148 in 3A, 451 
ValP814/IleP814 in VP1, AlaP1728/CysP1728/ValP1728 in 3C). These amino acid residues may be 452 
potential genetic determinants of virulence. Amongst all the 3 neurovirulent strains, 453 
SDLY107 varied in 4 nts. (CP579/TP579, CP241/TP241, AP571/TP571 in 5′-NTR and TP7335/CP7335 454 
in 3′-NTR), suggesting that these nt(s). may be genetic determinants of virulence (Wen et 455 
al., 2013). Liu et al. (2014) discovered that there were 9 aa. differences in the VP1 456 
sequences (E145G/Q, V249I, H22Q, P27S, N31S/D, E98K, D164E, T240A/S, A289T) in a 457 
comparison between fatal and mild EV-A71 strains (sub-genotype C4). These aa. could be 458 
possible genetic determinants of virulence in EV-A71 that could convert mild strains into 459 
fatal ones (Liu et al., 2014). The position of a single or a combination of aa. may have deep 460 
implications for virulence in different EV-A71 genotype/sub-genotype strains.  461 
Wang et al. (2012) performed analysis on seven EV-A71 sequences (sub-genotype C4) 462 
from HFMD patients in Changchun, China who suffered either mild or severe HFMD. 463 
They identified that these seven viruses were actually recombinant viruses evolved from 464 
different type A Enteroviruses. For example, these viruses contained genetic recombination 465 
events between CV-A4, CV-A5, and EV-A71 (sub-genotypes B4 and C1) and hence not 466 
surprisingly, most of the structural protein, P1 of these viruses resembled that of the 467 
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prototype EV-A71, sub-genotype C1 strains. There was also a very high amount of 468 
similarity between the non-structural proteins (P2 and P3) and CV-A4, CV-A5, with EV-469 
A71 (sub-genotype B4) in varying genomic regions possibly due to genomic recombination 470 
events. As our viral strain was also of sub-genotype B4, our working strain may have 471 
evolved from a single common ancestor that had continuously evolved over the years. This 472 
has serious implications as a virus that continuously undergoes genetic recombination could 473 
lead to the evolution of more virulent viruses. This would then make designing of a vaccine 474 
more difficult for such viruses that have high mutability rates (Wang et al., 2012). Hence, 475 
further studies such as phylogenetic analysis of isolates from mild/severe patients infected 476 
with EV-A71 (sub-genotype B4) should be carried out to determine the pattern of 477 
evolution.  478 
Interestingly, when Threonine at position 251 within the 3DPol region was substituted 479 
with Isoleucine (T251I), it altered the temperature susceptibility of EV-A71 (sub-genotype 480 
C2) from total susceptibility to complete resistance at 39.5oC in vitro. This strain also had 481 
increased viral virulence and showed clinical symptoms in vivo (Huang et al., 2015). The 482 
pathogenicity of mutant T251I was not evaluated in our investigation as the EV-A71 strain 483 
41 (sub-genotype B4) does not carry a threonine (T) at residue 251 when compared to the 484 
sub-genotype C2 in the study conducted by Huang et al. (2015). However, we constructed a 485 
mutant similar to that of Meng and Kwang (2014) who produced highly attenuated EV-A71 486 
mutants displaying high-fidelity with a single aa. change, (G64R) in its RdRP that greatly 487 
reduced pathogenicity in vivo. These EV-A71 mutants have lower pathogenicity as they are 488 
unable to generate replication-efficient mutations and have much lower genetic diversity to 489 
withstand a wide range of selective pressures. The authors postulate that the G64R mutant 490 
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could serve as a promising vaccine candidate as G64R mutant was genetically stable in the 491 
brain and muscle of infected mice at 12th-day post-infection (Meng and Kwang, 2014).  492 
Kataoka et al. (2013) discovered that if glutamic acid (E) was present at aa. VP1-145 493 
(sub-genotype C1), the virus induced neuro-pathogenesis and viremia more efficiently in 494 
cynomolgus monkeys than if glycine (G) was found at residue 145 (Kataoka et al., 2015). It 495 
was also demonstrated that the E145Q substitution within the VP1 region was a frequent 496 
change in the EV-A71 viral genomes of strains associated with mild and fatal HFMD cases. 497 
Generally, fatal strains had more substitutions in the IRES and 5’-NTR regions (Chang et 498 
al., 2012). This was of no surprise as these regions were responsible for receptor binding 499 
and translation of viral mRNA. The VP1-145 amino acid has been determined as a “hot 500 
spot” for evolutionary pressures on EV-A71 (Tee et al., 2010). In order to investigate the 501 
involvement of VP1-145 and G64R in the molecular basis of virulence in EV-A71 sub-502 
genotype B4, site directed mutagenesis at positions G64R and VP1-E145G was conducted 503 
at these 2 sites to analyze the effects of both the mutations on virulence.  504 
However, one of the disadvantages of a LAV would be its potential to revert back to 505 
wild type virulence, especially if the strain consists of “hot spots” for mutations. Hence, to 506 
boost the genetic stability of the LAV, multiple mutations were further introduced into the 507 
EV-A71 genome to reduce reversion and increase the stability of LAVs. The virulence of 508 
the different EV-A71 mutant strains was evaluated in the RD cell line by cytopathic effects, 509 
viral titer by tissue culture infectious dose (TCID50), plaque assays, detection of VP1 and 510 
real time determination of RNA copy number. After the effects brought about by each of 511 
the single site mutation and the partial deletion were quantified, the most significant 512 
mutations that could reduce virulence were selected and introduced into the PD mutant.  513 
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Hence, we had constructed a multiply mutated EV-A71 strain (MMS) by substituting six 514 
different nucleotides at U700C, VP1-E145G, VP1-242K, VP1-98E, VP1-244K, G64R 515 
(3Dpol) in the strain carrying a partial deletant (∆11bp) within the 5’-NTR region.  516 
Very little VP1 quantity was observed in the EV-A71 mutants having site specific 517 
mutations at nt. 475 and 487 in the 5’-NTR. An examination of the TCID50 values showed 518 
that the MMS needed significantly greater viral titer (3.16 X 108) to show CPE in 50% of 519 
the infected cells. This was to be expected as the MMS had lower infectivity in RD cells 520 
than the other codon deoptimized and SDM mutants. Significantly lower RNA copy 521 
numbers were obtained for 3 mutants (MMS, VP1-244K, VP1-E145G) at 1.3 X 102, 2.9 X 522 
102, and 4.5 X 102, respectively. Although the MMS could not totally eradicate viral 523 
replication, there was significant 105-fold decrease in viral growth.  524 
Subsequently, the number of plaques produced by the various mutant strains was 525 
examined in RD tissue culture by plaque assays. If the capability to form plaques is 526 
reduced, this would mean that viral growth is slower, thereby producing a lower PFU/ml 527 
value. For example, the mutant VP1-244K (2.5 x 105 PFU/mL) and mutant VP1-E145G 528 
showed significant decreases in plaque count (3.5 x 105 PFU/mL) in comparison to the EV-529 
A71 wild type (strain 41) with 8.0 x 108 PFU/mL. The lowest plaque count was formed by 530 
the MMS (1.2 x 104 PFU/mL) and mutant C475U (7.0 x104 PFU/mL). 531 
Some of the site directed mutations such as those introduced into sites at 475, 487, 532 
VP1-145, VP1-244 and a deletion in mutant PD were very effective in reducing cytopathic 533 
effects, RNA copy numbers, plaque count, VP1 amount and TCID50. By combining the 534 
beneficial mutations into a single vaccine strain, the MMS may serve as a potential LAV 535 
candidate for further evaluation by virulence testing in vivo. Attenuated strains with low 536 
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viral RNA copy number are possible good vaccine strains as they could not replicate fast 537 
enough to yield high viral load and cause destruction of the tissue cells. Slow replication 538 
could infer that the cells could still carry enough antigens to stimulate a good immune 539 
response.  540 
5. Conclusions 541 
This investigation has isolated and characterized several EV-A71 mutants with 542 
significant attenuation of viral virulence in Rhabdomyosarcoma cells. Better attenuated 543 
mutants could be constructed by introducing multiple mutations into the attenuated EV-544 
A71 mutant PD. It was discovered that EV-A71 mutants carrying mutations at C272U, 545 
U488C and U700C in the 5’-NTR were not highly attenuated as they still produced more 546 
RNA, VP1 protein, plaque count and had lower TCID50 values than other SDM and codon 547 
deoptimized mutants. Therefore, they are not significant virulence determinants for the wild 548 
type EV-A71 strain 41 (sub-genotype B4) in comparison to the sub-genotype C4 fatal 549 
strains studied by Li et al. (2011) (Li et al., 2011). The multiple mutations in the MMS did 550 
not totally eradicate the capability of the virus to multiply in vitro, but there were 551 
significant decreases in replication. Further studies should be conducted to investigate the 552 
stability of the MMS. A strain which is genetically highly stable and does not revert easily 553 
would thereby make a better LAV for EV-A71.  554 
The results support the hypothesis that every EV-A71 genotype or sub-genotype carries 555 
a different virulence determinant or a combination of significant virulence determinants. In 556 
a particular sub-genotype, there may be several amino acids that determine virulence; hence 557 
it is important to identify significant amino acid residues that could be combined in the 558 
rational design of effective LAVs Therefore, the results obtained in this study demonstrate 559 
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that quantifying the reduction of virulence through comparison of each SDM and partial 560 
deletion introduced into the genome is more effective than comparison of sequences 561 
between fatal and non-fatal strains.  562 
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Table 1. Cytopathic effects (CPE) caused by EV-A71 mutants and the positive control 670 
(wild type EV-A71 sub-genotype B4). 671 
EV-A71 Mutants CPE 
C475U 
A486G 
G487A 
VP1-98E 
+ 
+++ 
+ 
++ 
VP1-242K +++ 
VP1-244K + 
G64R (3Dpol) 
Partial Deletant (PD) 5’-NTR                                             
++ 
+ 
VP1-E145G 
VP2-149K 
2A-930K 
C272U 
U488C 
C700U 
Multiple Mutant strain (MMS) 
+ 
++++ 
++++ 
+++ 
+++     
++ 
+  
Positive control (wild type EV-A71) +++++ 
RD cells were infected with EV-A71 mutants and the positive control (wild type EV-A71 672 
sub-genotype B4) at a multiplicity of infection (MOI) of 0.1. 673 
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Figure 1. CPE by EV-A71 mutants (a) VP1-98E (b) VP1-242K (c) VP1-244K (d) G64R 
(e) PD (f) VP1-E145G (g) VP2-149K (h) 930K (2A) (i) C272U (j) U488C (k) C700U (l) 
Multiple Mutant strain (MMS) (m) C475U (n) A486G (o) G487A in RD cells compared 
with (p) uninfected RD cells (negative control) and (q) infected RD cells (positive control).  
                             
Figure 2. Logarithm Tissue Culture Infectious Dose 50 (Log TCID50) of EV-A71 mutants 
compared with the positive control (EV-A71 sub-genotype B4). The plate was placed at 
37oC for up to 48h and observed daily for CPE. The TCID50/ml values are determined 
based on the Reed and Muench formula from at least three independent experiments. 
 
Figure 3. Viral RNA copy number quantification. Transfection of infectious RNA of EV-
A71 mutants into RD cells was carried out with Lipofectamine 3000 reagent with a MOI of 
0.1. (+) control refers to wild type EV-A71 sub-genotype B4. (-) control refers to RD cells 
with no virus infection. The RNA copy number was calculated at 24h post-infection by 
TaqMan Real-Time PCR based on the average of at least three biological replicates. Error 
bars indicate the standard deviation ± mean.  
 
Figure 4. Western blot using monoclonal antibodies against VP1 as the primary antibody. 
The quantity of total proteins from EV-A71 and β-actin in each lane was 20 μg. The lanes 
are as follows: lane M, molecular weight marker (from 10 - 250 kilodaltons), lane 1, 
Mutant G64R; lane 2, Mutant VP1-98E; lane 3, Mutant VP1-E145G; lane 4, Mutant 
U488C; lane 5, Mutant G487A; lane 6, MMS; lane 7, A486G; lane 8, C475U; lane 9, 
Mutant VP1-242K; lane 10, Mutant VP1-244K; lane 11, Mutant C272U; lane 12, Mutant 
U700C; lane 13, Mutant Partial Deletant (PD); lane 14, VP2-149K; lane 15, 2A-930K; lane 
16, Positive control (EV-A71 strain 41); lane 17, Negative control (non-infected cells). The 
molecular weights of the VP1 protein and β-actin are 36 kDa and 42 kDa, respectively. 
 
Figure 5. Quantification of plaque counts by EV-A71 mutants and positive control 
(wild type EV-A71). The plaque assays were carried out on RD cells incubated at 37oC for 
48h from at least two independent experiments. 
 
Figure 6. Plaque Forming Units (PFU) by EV-A71 mutants in comparison with the 
positive control (wild type EV-A71). RD cells were transfected with EV-A71 mutants and 
the positive control at a MOI of 0.1. Plaques were observed 48 h post-infection. PFU values 
are calculated based on the average of at least 2 biological replicates and error bars 
represent the standard deviation ± mean.
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Table 1. Cytopathic effects (CPE) caused by EV-A71 mutants in comparison with the wild type EV-
A71 strain 41. 
EV-A71 Mutants CPE 
C475U 
A486G 
G487A 
VP1-98E 
+ 
+++ 
+ 
++ 
VP1-242K +++ 
VP1-244K + 
G64R (3Dpol) 
Partial Deletant (PD) 5’-NTR                                             
++ 
+ 
VP1-E145G 
VP2-149K 
2A-930K 
C272U 
T488C 
C700U 
Multiple Mutant strain (MMS) 
+ 
++++ 
++++ 
+++ 
+++     
++ 
+  
Positive Control (EV-A71 strain 41) +++++ 
RD cells were infected with the EV-A71 wild type and mutant viruses at a MOI of 0.1. The 
TCID
50
/ml values are calculated using the Reed and Muench formula determined from three 
independent experiments. 
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                   (a)                                         (b)                                          (c)                    (d)                                         (e)                                     (f) 
                                                    
       (g)                                         (h)                                           (i)                                  (j)                                          (k)                                (l)                                   
              
                        (m)                                         (n)          (o)                (p)                               (q)                                   
Figure 1. Cytopathic effects (CPE) caused by EV-A71 mutants (a) VP1-98E (b) VP1-242K (c) VP1-244K (d) G64R (e) PD (Partial Deletant 5’-NTR) (f) VP1-E145G (g) 
VP2-149K (h) 2A-930K (i) C272U (j) U488C (k) C700U (l) Multiple Mutant strain (MMS) (m) C475U (n) A486G (o) G487A in Rhabdomyosarcoma (RD) cells in 
comparison with (p) uninfected RD cells (negative control using Opti-MEM) and (q) EV-A71 wild type strain 41 infected RD cells (positive control).  
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Figure 2. Logarithm Tissue Culture Infectious Dose 50 (Log TCID50) of EV-A71 mutants in comparison with the wild type EV-A71 sub-genotype B4 strain 41. The 
plate was incubated at 37oC and observed daily for CPE up to 48h. The TCID50/ml values are calculated using the Reed and Muench formula determined from at 
least three independent experiments. 
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Figure 3. Quantification of Viral RNA Copy Number. Transfection of infectious RNA into RD cells was performed with the use of Lipofectamine 2000 reagent 
using EV-A71 mutants with a MOI of 0.1. (+) control refers to the EV-A71 sub-genotype B4 strain 41. (-) control refers to the RD cells with no virus infection. The 
viral RNA copy number was determined at 24h post-infection by TaqMan Real-Time PCR. Viral RNA copy numbers are the average of three biological replicates. 
Error bars represent the standard deviation of the mean.  
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Figure 4. Western blot analysis using monoclonal antibody against VP1 as the primary antibody. The amount of EV-A71 total proteins and β-actin loaded in each 
lane was 20 μg. The lanes are as follows: lane M, molecular weight marker (from 10 - 250 kilodaltons), lane 1, EV-A71 Mutant G64R; lane 2, Mutant VP1-98E; lane 
3, Mutant VP1-E145G; lane 4, Mutant U488C; lane 5, Mutant G487A; lane 6, MMS; lane 7, A486G; lane 8, C475U; lane 9, Mutant VP1-242K; lane 10, Mutant VP1-
244K; lane 11, Mutant C272U; lane 12, Mutant U700C; lane 13, Mutant Partial Deletant (PD); lane 14, VP2-149K; lane 15, 2A-930K; lane 16, Positive control (EV-
A71 strain 41); lane 17, Negative control (uninfected RD cells). The molecular weights of the EV-A71 protein and β-actin are 36 kDa and 42 kDa, respectively. 
 
 
 
 
 
 5 
 
(a) Positive control 
 
                    
 
Viral count: 8.0x108 
 
(b) VP1 (E145G)    
      
     
 
Viral count: 3.5x105 
(c) 3D (G64R) 
  
 
 
Viral count: 6.0x106 
(d) C475U    
     
 
 
Viral count: 7.0x104 
(e) A486G 
 
    
 
Viral count: 2.3x107 
 
(f) U488C 
       
 
 
Viral count: 2.3x107 
 
(g) VP1-242K 
 
 
 
Viral count: 2.0x107 
 
(h) C272U 
 
 
 
Viral count: 5.7x107 
 
(i) VP1-244K 
       
 
 
Viral count: 2.5x105 
       
(j) C700U 
 
 
 
Viral count: 2.0x107 
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(j) Partial Deletant (PD) 
 
 
 
Viral count: 1.0x105 
 
(l) VP2-149K 
 
 
 
Viral count: 9.9x107 
(m) 2A-930K 
 
 
 
Viral count: 7.0x107 
          (n) VP1-98E 
  
      
 
Viral count: 7.5x105 
(o) G487A 
 
      
 
Viral count: 1.4x105 
(p) MMS 
 
(q) Negative control 
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Viral count: 1.2x104 
 
 
Viral count: 0 
 
Figure 5. Quantification of plaque forming units by EV-A71 mutants and wild type EV-A71 strain 41. The plaque assays were performed on monolayer RD 
cells incubated at 37oC and were repeated at least two separate times. 
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Figure 6. Plaque Forming Units by EV-A71 mutants and the wild type EV-A71 strain 41. RD cells were transfected with EV-A71 mutants and the wild type EV-
A71 strain 41 at a MOI of 0.1. Plaque formation was observed 48 hours post-infection. PFU numbers are the average of two biological replicates; Error bars 
represent the standard deviation of the mean. 
